Ignite Creation Date:
2025-12-25 @ 12:28 AM
Ignite Modification Date:
2026-01-22 @ 2:42 AM
Study NCT ID:
NCT03635567
Status:
COMPLETED
Last Update Posted:
2025-05-11
First Post:
2018-08-15
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-25
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-06-04
Completion Date Type:
ACTUAL
First Submit Date:
2018-08-15
First Submit QC Date:
None
Study First Post Date:
2018-08-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-09-20
Results First Submit QC Date:
None
Results First Post Date:
2023-10-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-29
Last Update Post Date:
2025-05-11
Last Update Post Date Type:
ACTUAL